187 related articles for article (PubMed ID: 9731468)
1. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
2. Immunoexpression of mutant p53 and human papillomavirus related E6 oncoprotein in anal malignancies.
Gupta S; Sharma BK
Indian J Exp Biol; 1998 Sep; 36(9):875-8. PubMed ID: 9854426
[TBL] [Abstract][Full Text] [Related]
3. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
4. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
7. p53 overexpression and human papillomavirus (HPV) infection in oesophageal squamous cell carcinomas derived from a high-incidence area in China.
Chang F; Syrjänen S; Wang L; Shen Q; Syrjänen K
Anticancer Res; 1997; 17(1B):709-15. PubMed ID: 9066606
[TBL] [Abstract][Full Text] [Related]
8. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
9. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.
Storey A; Thomas M; Kalita A; Harwood C; Gardiol D; Mantovani F; Breuer J; Leigh IM; Matlashewski G; Banks L
Nature; 1998 May; 393(6682):229-34. PubMed ID: 9607760
[TBL] [Abstract][Full Text] [Related]
10. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
11. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
Pim D; Banks L
Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
[TBL] [Abstract][Full Text] [Related]
12. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
13. HPV-16 E6 oncoprotein induces mutations via p53-dependent and -independent pathways.
Kim HJ; Guo W; Park NH
Oncol Rep; 2000; 7(4):707-12. PubMed ID: 10854530
[TBL] [Abstract][Full Text] [Related]
14. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
15. [Detection of HPV in human esophageal cancer in high-incidence area and its correlation with p53 expression].
Lu Z; Chen K; Guo M
Zhonghua Zhong Liu Za Zhi; 2001 May; 23(3):220-3. PubMed ID: 11783091
[TBL] [Abstract][Full Text] [Related]
16. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].
Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346
[TBL] [Abstract][Full Text] [Related]
17. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
Pim D; Massimi P; Banks L
Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes.
Nees M; Geoghegan JM; Munson P; Prabhu V; Liu Y; Androphy E; Woodworth CD
Cancer Res; 2000 Aug; 60(15):4289-98. PubMed ID: 10945644
[TBL] [Abstract][Full Text] [Related]
19. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines.
Liang XH; Volkmann M; Klein R; Herman B; Lockett SJ
Oncogene; 1993 Oct; 8(10):2645-52. PubMed ID: 8397367
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells.
Pim D; Storey A; Thomas M; Massimi P; Banks L
Oncogene; 1994 Jul; 9(7):1869-76. PubMed ID: 8208532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]